AI-developed Immunotherapy in Metastatic Melanoma Found Positive
Copenhagen-based Evaxion Biotech A/S announced today results from its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of cancer immunotherapy EVX-02 adjuvant melanoma.
Data from the trial of EVX-01, a novel patient-specific cancer neoepitope immunotherapy based on Evaxion’s PIONEER AI technology combined with a PD-1 checkpoint inhibitor, showed a safety profile with only Grade 1 and 2 adverse events observed.
Combined therapy with EVX-01 demonstrated an objective response rate of 67% across all nine patients compared with historical data of 40% with anti-PD1 treatment alone.
The study also demonstrated a complete response rate of 22%, compared with a historical 7% with anti-PD1 treatment alone, and a partial response rate of 44%, versus 33% compared with anti-PD1 treatment alone.
Among the four patients on the highest two doses, there was an objective response rate of 75%In addition, three patients with Stable Disease for 10, 8, and 9 months on anti-PD1 treatment alone achieved CR, CR, and PR respectively following EVX-01 administration and subsequent activation of a neoepitope-specific de novo T-cell response.
Evaxion Biotech A/S is a clinical-stage AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and vaccines against bacterial diseases and viral infections.